431940-36-2

Basic information

• Product Name: 2-(4-methylphenyl)-2-oxoethyl 2-(methylamino)benzoate
• Synonyms: 2-(4-methylphenyl)-2-oxoethyl 2-(methylamino)benzoate
• CAS NO: 431940-36-2
• Molecular Formula: C17H17NO3
• Molecular Weight: 283.32178
• Mol File: 431940-36-2.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(4-methylphenyl)-2-oxoethyl 2-(methylamino)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-methylphenyl)-2-oxoethyl 2-(methylamino)benzoate(431940-36-2)
• EPA Substance Registry System: 2-(4-methylphenyl)-2-oxoethyl 2-(methylamino)benzoate(431940-36-2)

Safety Data

• Hazardous Substances Data: 431940-36-2(Hazardous Substances Data)

Upstream product

• 119-68-6 N-Methylanthranilic acid 
• 619-41-0 4-(bromoacetyl)toluene 

Relevant articles and documents

Synthesis and fluorescence properties of 2-aryl-3-hydroxyquinolones, a new class of dyes displaying dual fluorescence

A series of 2-aryl-3-hydroxyquinolones (3HQs) with different electron donating aryl substituents at the position 2 were synthesized. Their absorption and fluorescence properties were studied in solvents of medium and high polarity. Almost all the synthesi

HETEROCYCLIC COMPOUNDS THAT BLOCK THE EFFECTS OF ADVANCED GLYCATION END PRODUCTS (AGE)

The present invention relates to novel compounds of Formula (Ia) or (Ib), their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. Formula (Ia), or Formula (Ib) in the above formulae L represents Formula (I), Formula (II) or -(CH2)1- Q represents Formula (III), or Formula (IV). The present invention also relates to a process for the preparation of the above said novel compounds, their pharmaceutically acceptable salts and pharmaceutical compositions containing them. The present invention also relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory responses in tissues, including endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. The present invention also relates to compounds that act as modulators of Perlecan activity and expression. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating heparan sulfate proteoglycans (HSPG) such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as stenosis, restenosis, neointimal hyperplasia, and atherosclerosis. The compounds of Formula (I) are also useful for the treatment and/or prevention of cancer. The types of cancers include melanoma, prostate, leukemia, lymphoma, non-small lung cancers, cancer of the central nervous system, breast, colon, ovarian or renal cancer.